Effect of variation in CYP11B1 and CYP11B2 on corticosteroid phenotype and hypothalamic-pituitary-adrenal axis activity in hypertensive and normotensive subjects

Clinical Endocrinology

Volumn 68, Issue 5, 2008, Pages 700-706

  Freel, E M ^a   Ingram, M ^a   Wallace, A M ^b   White, A ^c   Fraser, R ^a   Davies, E ^a   Connell, J M C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NHS Greater Glasgow and Clyde Clinical Biochemistry Service   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; CORTICOSTEROID; CORTICOTROPIN; CORTODOXONE; DEXAMETHASONE; HYDROCORTISONE; STEROID 11BETA MONOOXYGENASE;

5' UNTRANSLATED REGION; ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; CYP11B1 GENE; CYP11B2 GENE; GENE; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROXYLATION; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IN VITRO STUDY; IN VIVO STUDY; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ALDOSTERONE SYNTHASE; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENETIC VARIATION; HUMANS; HYPERTENSION; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; PHENOTYPE; PITUITARY-ADRENAL SYSTEM; STEROID 11-BETA-HYDROXYLASE; UP-REGULATION;

EID: 42149174492     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2007.03116.x     Document Type: Article

References (28)

1. Gordon, R.D., Stowasser, M., Tunny, T.J., Klemm, S.A. Rutherford, J.C. (1994) High incidence of primary aldosteronism in 199 patients referred with hypertension. Clinical and Experimental Pharmacology and Physiology, 21, 315 318.
2. Lim, P.O., Rodgers, P., Cardale, K., Watson, A.D. Macdonald, T.M. (1999) Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet, 353, 1013.
3. Olivieri, O., Ciacciarelli, A., Signorelli, D., Pizzolo, F., Guarini, P., Pavan, C., Corgnati, A., Falcone, S., Corrocher, R., Micchi, A., Cressoni, C. Blengio, G. (2004) Aldosterone to Renin ratio in a primary care setting: the Bussolengo study. Journal of Clinical Endocrinology and Metabolism, 89, 4221 4226.
4. Kaplan, N.M. (2004) The current epidemic of primary aldosteronism: causes and consequences. Journal of Hypertension, 22, 863 869.
5. Mulatero, P., Stowasser, M., Loh, K.C., Fardella, C.E., Gordon, R.D., Mosso, L., Gomez-Sanchez, C.E., Veglio, F. Young, W.F. Jr. (2004) Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. Journal of Clinical Endocrinology and Metabolism, 89, 1045 1050.
6. Pitt, B., Zannad, F., Remme, W.J., Cody, R., Castaigne, A., Perez, A., Palensky, J. Wittes, J. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. New England Journal of Medicine, 341, 709 717.
7. Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., Gatlin, M. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy Survival Study Investigators (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New England Journal of Medicine, 348, 1309 1321.
8. Beygui, F., Collet, J.P., Benoliel, J.J., Vignolles, N., Dumaine, R., Barthelemy, O. Montalescot, G. (2006) High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation, 114, 2604 2610.
9. Milliez, P., Girerd, X., Plouin, P.F., Blacher, J., Safar, M.E. Mourad, J.J. (2005) Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. Journal of the American College of Cardiology, 45, 1243 1248.
10. Mornet, E., Dupont, J., Vitek, A. White, P.C. (1989) Characterization of two genes encoding human steroid 11-β-hydroxylase (P-450 (11) β). Journal of Biological Chemistry, 264, 20961 20967.
11. White, P.C. Slutsker, L. (1995) Haplotype analysis of CYP11B2. Endocrine Research, 21, 437 442.
12. Lim, P.O., Macdonald, T.M., Holloway, C., Friel, E., Anderson, N.H., Dow, E., Jung, R.T., Davies, E., Fraser, R. Connell, J.M. (2002) Variation at the aldosterone synthase (CYP11B2) locus contributes to hypertension in subjects with a raised aldosterone-to-renin ratio. Journal of Clinical Endocrinology and Metabolism, 87, 4398 4402.
13. Paillard, F., Chansel, D., Brand, E., Benetos, A., Thomas, F., Czekalski, S., Ardaillou, R. Soubrier, F. (1999) Genotype-phenotype relationships for the renin-angiotensin-aldosterone system in a normal population. Hypertension, 34, 423 429.
14. Davies, E., Holloway, C.D., Ingram, M.C., Inglis, G.C., Friel, E.C., Morrison, C., Anderson, N.H., Fraser, R. Connell, J.M. (1999) Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2. Hypertension, 33, 703 707.
15. Sookoian, S., Gianotti, T.F., Gonzalez, C.D. Pirola, C.J. (2007) Association of the C-344T aldosterone synthase gene variant with essential hypertension: a meta-analysis. Journal of Hypertension, 25, 5 13.
16. Pojoga, L., Gautier, S., Blanc, H., Guyene, T.T., Poirier, O., Cambien, F. Benetos, A. (1998) Genetic determination of plasma aldosterone levels in essential hypertension. American Journal of Hypertension, 11, 856 860.
17. Tsukada, K., Ishimitsu, T., Teranishi, M., Saitoh, M., Yoshii, M., Inada, H., Ohta, S., Akashi, M., Minami, J., Ono, H., Ohrui, M. Matsuoka, H. (2002) Positive association of CYP11B2 gene polymorphism with genetic predisposition to essential hypertension. Journal of Human Hypertension, 16, 789 793.
18. Kumar, N.N., Benjafield, A.V., Lin, R.C., Wang, W.Y., Stowasser, M. Morris, B.J. (2003) Haplotype analysis of aldosterone synthase gene (CYP11B2) polymorphisms shows association with essential hypertension. Journal of Hypertension, 21, 1331 1337.
19. Davies, E., Holloway, C.D., Ingram, M.C., Friel, E.C., Inglis, G.C., Swan, L., Hillis, W.S., Fraser, R. Connell, J.M. (2001) An influence of variation in the aldosterone synthase gene (CYP11B2) on corticosteroid responses to ACTH in normal human subjects. Clinical Endocrinology, 54, 813 817.
20. Connell, J.M., Fraser, R., MacKenzie, S. Davies, E. (2003) Is altered adrenal steroid biosynthesis a key intermediate phenotype in hypertension? Hypertension, 41, 993 999.
21. Keavney, B., Mayosi, B., Gaukrodger, N., Imrie, H., Baker, M., Fraser, R., Ingram, M., Watkins, H., Farrall, M., Davies, E. Connell, J. (2005) Genetic variation at the locus encompassing 11-β hydroxylase and aldosterone synthase accounts for heritability in cortisol precursor (11-deoxycortisol) urinary metabolite excretion. Journal of Clinical Endocrinology and Metabolism, 90, 1072 1077.
22. Barr, M., MacKenzie, S.M., Friel, E.C., Holloway, C.D., Wilkinson, D.M., Brain, N.J., MacKenzie, S., Fraser, R., Dominiczak, A., Davies, E. Connell, J. (2007) Polymorphic variation in the 11β-hydroxylase gene associates with reduced 11-hydroxylase efficiency. Hypertension, 49, 113 119.
23. Williams, B., Poulter, N.R., Brown, M.J., Davis, M., McInnes, G.T., Potter, J.F., Sever, P.S. Thom, S.M. (2004) BHS guidelines working party, for the British Hypertension Society 2004 British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. British Medical Journal, 328, 634 640.
24. Dobson, S.H., Gibson, S. White, A. (1989) Assessment of the potency of different standards in the immunoradiometric assay of ACTH. Annals of Clinical Biochemistry, 26, 96 101.
25. Millar, J.A., Leckie, B.J., Morton, J.J., Jordan, J. Tree, M. (1980) A microassay for active and total renin concentration in human plasma based on antibody trapping. Clinica Chimica Acta, 101, 5 15.
26. Al-Hashmi, K., Wallace, A. Connell, J. (2005) The aldosterone/renin ratio using renin concentration compared to renin activity in a healthy population. Endocrine Abstracts, 9, 145.
27. Barr, C.S., Lang, C.C., Hanson, J., Arnott, M., Kennedy, N. Struthers, A.D. (1995) Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. American Journal of Cardiology, 76, 1259 1265.
28. Niarchos, A.P., Weinstein, D.L. Laragh, J.H. (1984) Comparison of the effects of diuretic therapy and low sodium intake in isolated systolic hypertension. American Journal of Medicine, 77, 1061 1068.